A5085172191- Renal cell carcinoma treatment
- Bladder and Urothelial Cancer Treatments
- Renal and related cancers
- Urinary and Genital Oncology Studies
- Cancer Genomics and Diagnostics
- Urological Disorders and Treatments
- Multiple and Secondary Primary Cancers
- Pediatric Urology and Nephrology Studies
- Prostate Cancer Diagnosis and Treatment
- MRI in cancer diagnosis
- Renal and Vascular Pathologies
- Epigenetics and DNA Methylation
- Cancer Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
- Prostate Cancer Treatment and Research
- Esophageal Cancer Research and Treatment
- Cancer, Hypoxia, and Metabolism
- Urologic and reproductive health conditions
- Genetic factors in colorectal cancer
- Ureteral procedures and complications
- Genetic and Kidney Cyst Diseases
- Tuberous Sclerosis Complex Research
- Radiomics and Machine Learning in Medical Imaging
- Organ Donation and Transplantation
The University of Texas MD Anderson Cancer Center
2016-2025
Centre Hospitalier de l’Université de Montréal
2025
Fox Chase Cancer Center
2024
Anderson University - South Carolina
2024
On Our Own of Maryland (United States)
2024
Stanford Medicine
2024
Seattle University
2024
Iowa Oncology Research Association
2024
GTx (United States)
2019-2022
Mayo Clinic
2021
No AccessJournal of UrologyAdult Urology1 Oct 2009Guideline for Management the Clinical T1 Renal Massis accompanied byIncreased Tissue Factor Expression and Poor Nephroblastoma PrognosisPercutaneous Microwave Ablation or Nephrectomy VX-2 Carcinoma in Rabbit KidneyTemporary Segmental Artery Occlusion Using Reverse Phase Polymer Bloodless Robotic Partial Steven C. Campbell, Andrew Novick, Arie Belldegrun, Michael L. Blute, George K. Chow, Ithaar H. Derweesh, Martha M. Faraday, Jihad Kaouk,...
The literature on upper tract urothelial carcinoma (UTUC) has been limited to small, single center studies. A large series of patients treated with radical nephroureterectomy for UTUC were studied, and variables associated poor prognosis identified.Data 1363 at 12 academic centers collected. All pathologic slides re-reviewed by genitourinary pathologists according strict criteria.Pathologic review revealed renal pelvis location (64%), necrosis (21.6%), lymphovascular invasion (LVI) (24.8%),...
No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Jul 2003Comparative Analysis Laparoscopic Versus Open Partial Nephrectomy for Renal Tumors in 200 Patients INDERBIR S. GILL, SURENA F. MATIN, MIHIR M. DESAI, JIHAD H. KAOUK, ANDREW STEINBERG, E.D. MASCHA, JULIE THORNTON, MAHMOUD SHERIEF, BRENDA STRZEMPKOWSKI, and C. NOVICK GILLINDERBIR GILL More articles by this author , MATINSURENA MATIN DESAIMIHIR DESAI KAOUKJIHAD KAOUK STEINBERGANDREW STEINBERG MASCHAE.D. MASCHA THORNTONJULIE...
No AccessJournal of UrologyAdult Urology: Oncology: Renal/Upper Tract/Bladder1 Jan 2005PROSPECTIVE RANDOMIZED COMPARISON OF TRANSPERITONEAL VERSUS RETROPERITONEAL LAPAROSCOPIC RADICAL NEPHRECTOMY MIHIR M. DESAI, BRENDA STRZEMPKOWSKI, SURENA F. MATIN, ANDREW P. STEINBERG, CHRISTOPHER NG, ANOOP MERANEY, JIHAD H. KAOUK, and INDERBIR S. GILL DESAIMIHIR DESAI More articles by this author , STRZEMPKOWSKIBRENDA STRZEMPKOWSKI MATINSURENA MATIN STEINBERGANDREW STEINBERG NGCHRISTOPHER NG MERANEYANOOP...
Renal cell carcinoma (RCC) is an immunogenic and proangiogenic cancer, antiangiogenic therapy the current mainstay of treatment. Patients with RCC develop innate or adaptive resistance to therapy. There a need identify biomarkers that predict therapeutic guide combination We assessed interaction between tumor immune microenvironment determined their impact on clinical outcome. found therapy-treated primary tumors showed increased infiltration CD4(+) CD8(+) T lymphocytes, which was inversely...
Upper tract urothelial carcinoma (UTUC) is characterized by a distinctly aggressive clinical phenotype. To define the biological features driving this phenotype, we performed an integrated analysis of whole-exome and RNA sequencing UTUC. Here report several key insights from our molecular dissection disease: 1) Most UTUCs are luminal-papillary; 2) UTUC has T-cell depleted immune contexture; 3) High FGFR3 expression enriched in correlates with its microenvironment; 4) Sporadic lower total...
The purpose of this guideline is to provide a useful reference on the effective evidence-based diagnoses and management non-metastatic upper tract urothelial carcinoma (UTUC).The Pacific Northwest Evidence-based Practice Center Oregon Health & Science University (OHSU) team conducted searches in Ovid MEDLINE (1946 March 3rd, 2022), Cochrane Central Register Controlled Trials (through January Database Systematic Reviews 2022). were updated August 2022. When sufficient evidence existed, body...
No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Dec 2001RENAL OUTCOME 25 YEARS AFTER DONOR NEPHRECTOMY DAVID A. GOLDFARB, SURENA F. MATIN, WILLIAM E. BRAUN, MARTIN J. SCHREIBER, BARBARA MASTROIANNI, DOREEN PAPAJCIK, HENRY ROLIN, STUART FLECHNER, MARLENE GOORMASTIC, and ANDREW C. NOVICK GOLDFARBDAVID GOLDFARB , MATINSURENA MATIN BRAUNWILLIAM BRAUN SCHREIBERMARTIN SCHREIBER MASTROIANNIBARBARA MASTROIANNI PAPAJCIKDOREEN PAPAJCIK ROLINHENRY ROLIN FLECHNERSTUART FLECHNER...
Abstract BACKGROUND: The authors evaluated the incidence of pathologic downstaging and complete remission (CR) in patients with high‐grade ureteral renal pelvic transitional cell carcinoma (TCC) (upper tract TCC) who received neoadjuvant chemotherapy followed by surgery. METHODS: study group comprised biopsy‐demonstrated, disease nephrouterectomy from 2004 to 2008, during which time uniformly were considered for chemotherapy. control underwent initial nephroureterectomy 1993 2004, when...
Abstract BACKGROUND: The benefits of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC) should outweigh surgical morbidity. Even when the generally agreed upon selection criteria for CN are met, some patients do poorly after surgery. objective this study was to identify preoperative factors that were prognostic outcome who being considered CN. METHODS: authors conducted a retrospective investigate overall survival (OS) underwent using OS with mRCC did not undergo as...
No AccessJournal of UrologyAdult urology1 Nov 2006Residual and Recurrent Disease Following Renal Energy Ablative Therapy: A Multi-Institutional Studyis corrected byResidual After Therapy Surena F. Matin, Kamran Ahrar, Jeffrey A. Cadeddu, Debra Gervais, Francis J. McGovern, Ronald Zagoria, Robert G. Uzzo, John Haaga, Martin I. Resnick, Jihad Kaouk, Inderbir S. Gill MatinSurena Matin Department Urology, University Texas M. D. Anderson Cancer Center, Houston , AhrarKamran Ahrar Interventional...
Purpose To assess safety and efficacy of presurgical bevacizumab in patients with metastatic renal cell carcinoma (mRCC), to explore the hypothesis that pretreatment antiangiogenic therapy will select who benefit most from cytoreductive nephrectomy. Patients Methods newly diagnosed, clear mRCC whose primary tumors were considered resectable enrolled. In this single-arm, phase II trial, received plus erlotinib (first patients, n = 23) or alone (n 27 patients) for 8 weeks followed by...
BACKGROUND High‐grade upper tract urothelial carcinoma (UTUC) is frequently upstaged after surgery and associated with uniformly poor survival. Neoadjuvant chemotherapy may offer a way to improve clinical outcomes. The authors compared the survival rates of patients UTUC who received neoadjuvant before among did not. METHODS A retrospective review was conducted high‐risk followed by from 2004 2008 (study group) matched cohort underwent initial 1993 2003 (control group). Fisher exact tests,...
Targeted molecular therapies such as bevacizumab, sunitinib and sorafenib before surgical resection hold promise rational treatment paradigms for patients with metastatic or locally recurrent renal cell carcinoma. To analyze the safety of this approach we evaluated parameters perioperative complications in treated targeted cytoreductive nephrectomy retroperitoneal carcinoma recurrence, compared them to a matched patient cohort who underwent up-front resection.We 44 local 58 surgery.Cohorts...